Neuropathy

The Education of Dispensary Staff is Varied and Lacks Regulation

Training and Practices of Cannabis Dispensary Staff

How much medical training does your local budtender possess? An online survey sent to medical marijuana dispensary staff reported only 55% of staffers had any formal training for their position, with 20% reporting some background in medical/scientific training. The analysis reported that many among the dispensary staff are recommending cannabis choices that are consistent with current evidence, but some are recommending strains that are either ineffective or exacerbate a patient’s condition. The findings of this study stress the importance of consistent and well-regulated training of dispensary staff.

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2FfJNSC     inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDThe Education of Dispensary Staff is Varied and Lacks Regulation
read more

Video: Cannabis For Symptoms of chronic pain, seizures, and inflammation

View this review (yellow link) or download:

This paper is also stored here:   http://bit.ly/2l4sexZ      inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDVideo: Cannabis For Symptoms of chronic pain, seizures, and inflammation
read more

Synthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases

Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses

A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.

View this review (yellow link) or download:

This paper is also stored here:  http://bit.ly/2HZ6cWb  inside the CED Foundation Archive

To explore related information, click keywords:

Benjamin Caplan, MDSynthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases
read more

Some, But Not Enough Data on Cannabis for Chronic Pain

Overlaps in pharmacology for the treatment of chronic pain and mental health disorders

Select small trials have demonstrated cannabis to be more effective than other analgesics to treat chronic pain associated with certain conditions. However, the existing research lacks large-scale, controlled experiments relating medical cannabis use to pain management. Additionally, negative effects are documented with respect to cannabis use among adolescents and those suffering from compromised mental health. There is a need for further research on the topic.

View this review (yellow link) or download:

This paper is also stored here: http://bit.ly/2wtvpRY inside the CED Foundation Archive

To explore related information, click keywords:

Benjamin Caplan, MDSome, But Not Enough Data on Cannabis for Chronic Pain
read more

Video: Medical Marijuana: What Physicians Need to Know

A video adaptation of “Medical Marijuana: What Physicians Need to Know”

This paper is also stored here:   (http://bit.ly/2KxqoAe)      inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDVideo: Medical Marijuana: What Physicians Need to Know
read more

Sativex Reduces MS-Related Spasticity

Delta-9-Tetrahydrocannabidiol Oromucosal Spray (Sativex): A Review in Multiple Sclerosis-Related Spasticity

A debilitating symptom of multiple sclerosis (MS) is spasticity, the stiffness and involuntary spasms of muscles, often occurring in the legs. In a randomized study involving MS patients who have not experienced relief with any current anti-spasticity medication, Sativex, a THC/CBD oro-mucosal spray was administered. Patients receiving THC/CBD experienced significantly more spasticity relief than the placebo group. Sativex may hold substantial treatment potential for MS patients, as side effects are minimized, the spray allows for an adjustable dosage, and there is low potential for abuse.

While this pharmaceutical is proving to be effective, in related data, we also see a distinct advantage of non-pharmaceutical options, including cost, availability, and efficacy, although drastically higher variability and limited consistency in product.

http://bit.ly/2WwVoqA

Benjamin Caplan, MDSativex Reduces MS-Related Spasticity
read more

Certain Cannabinoids may be Effective Co-Therapies for Neuropathic or MS pain

In a systematic review of studies investigating cannabis therapy for the treatment of chronic non-cancer pain (CNCP), evidence pointed to cannabinoids primarily effecting change with respect to neuropathy or MS-related pain. For CNCPs, it is unlikely that cannabinoids can be used as a single therapy, but rather in conjunction with other therapies. The quality of evidence in many of the studies reviewed was low, so further research needs to be completed in order to evaluate the efficacy of cannabinoids as a long-term treatment option for CNCPs.

Read more here:

This paper is stored here: http://bit.ly/2IgOLiG inside the CED Foundation Archive To explore related literature, click keywords below:

Benjamin Caplan, MDCertain Cannabinoids may be Effective Co-Therapies for Neuropathic or MS pain
read more